S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
Expanded IRS free-file system one step closer in Dems' bill
Climate bill: Could coal communities shift to nuclear?
Germans urged to cap heat in offices this winter to save gas
New $2.2 Quadrillion Trend About To Open Up (Ad)pixel
The 7 Types Of People Every Entrepreneur Needs In Their Inner Circle -- And How To Find Them
Former Deutsche Bank Co-CEO Anshu Jain dies
Germany urged to cap heat in offices this winter to save gas
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
NASDAQ:MASI

Masimo - MASI Stock Forecast, Price & News

$154.37
+1.16 (+0.76%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$150.67
$155.26
50-Day Range
$122.02
$157.78
52-Week Range
$112.07
$305.21
Volume
1.68 million shs
Average Volume
1.06 million shs
Market Capitalization
$8.11 billion
P/E Ratio
46.50
Dividend Yield
N/A
Price Target
$183.80

Masimo MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
19.1% Upside
$183.80 Price Target
Short Interest
Bearish
7.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.86
Upright™ Environmental Score
News Sentiment
0.60mentions of Masimo in the last 14 days
Based on 28 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.42%
From $4.47 to $5.07 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

698th out of 1,135 stocks

Electromedical Equipment Industry

14th out of 25 stocks

MASI stock logo

About Masimo (NASDAQ:MASI) Stock

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry. It also provides Masimo rainbow SET platform that includes rainbow SET Pulse CO-Oximetry products that noninvasively monitor hemoglobin species, including oxygen saturation, pulse rate, perfusion index, pleth variability index, and respiration rate from the pleth; noninvasively monitor hemoglobin concentration, and carboxyhemoglobin and methemoglobin; monitor arterial oxygen saturation and acoustic respiration rate; and calculates oxygen content and oxygen reserve index. It offers SedLine brain function monitoring technology to measure the brain's electrical activity by detecting EEG signals; capnography and gas monitoring products comprising external plug-in-and-measure capnography and gas analyzers, integrated modules, handheld capnograph and capnometer devices, and capnography sampling lines; O3 regional oximetry for tissue oxygen saturation measurement; and hemodynamic monitoring solutions. Its Masimo Hospital Automation platform includes Patient SafetyNet, Patient SafetyNet surveillance, Kite, UniView, Replica, UniView : 60, and MyView. It offers connectivity devices; and nasal high flow ventilation and neuromodulation solutions. It provides its products through direct sales force, distributors, and original equipment manufacturers partners to hospitals, emergency medical service and home care providers, long-term care facilities, physician offices, veterinarians, and consumers; and non-medical/consumer products through e-commerce site, masimopersonalhealth.com. The company was incorporated in 1989 and is headquartered in Irvine, California.

Analysts Set New Price Targets

Several brokerages have recently weighed in on MASI. Needham & Company LLC lifted their price objective on Masimo from $163.00 to $179.00 and gave the stock a "buy" rating in a report on Wednesday. Piper Sandler increased their price objective on shares of Masimo from $130.00 to $135.00 and gave the company a "neutral" rating in a research note on Wednesday. Stifel Nicolaus lowered their target price on shares of Masimo from $175.00 to $150.00 in a research note on Wednesday, May 4th. Finally, StockNews.com cut shares of Masimo from a "buy" rating to a "hold" rating in a research note on Wednesday. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $183.80.

Masimo Price Performance

MASI Stock opened at $154.37 on Friday. The stock has a 50-day moving average price of $137.78 and a two-hundred day moving average price of $148.07. Masimo has a 1 year low of $112.07 and a 1 year high of $305.21. The stock has a market cap of $8.11 billion, a PE ratio of 46.50 and a beta of 0.98. The company has a current ratio of 2.10, a quick ratio of 3.98 and a debt-to-equity ratio of 0.77.

Masimo (NASDAQ:MASI - Get Rating) last announced its earnings results on Tuesday, August 9th. The medical equipment provider reported $1.35 EPS for the quarter, topping the consensus estimate of $1.19 by $0.16. The business had revenue of $565.30 million during the quarter, compared to analysts' expectations of $540.56 million. Masimo had a net margin of 12.68% and a return on equity of 17.39%. The firm's revenue was up 87.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.94 earnings per share. Equities analysts forecast that Masimo will post 4.47 EPS for the current fiscal year.

Receive MASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.

MASI Stock News Headlines

StockNews.com Downgrades Masimo (NASDAQ:MASI) to Hold
Masimo (NASDAQ:MASI) PT Raised to $135.00 at Piper Sandler
Masimo Reports Second Quarter 2022 Financial Results
See More Headlines
Receive MASI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter.

MASI Company Calendar

Last Earnings
8/09/2022
Today
8/14/2022
Next Earnings (Estimated)
10/25/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:MASI
CUSIP
57479510
Employees
6,200
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$183.80
High Stock Price Forecast
$295.00
Low Stock Price Forecast
$135.00
Forecasted Upside/Downside
+19.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

Net Income
$229.65 million
Pretax Margin
15.29%

Debt

Sales & Book Value

Annual Sales
$1.24 billion
Cash Flow
$4.80 per share
Book Value
$22.90 per share

Miscellaneous

Free Float
47,435,000
Market Cap
$8.11 billion
Optionable
Optionable
Beta
0.98

Social Links















MASI Stock - Frequently Asked Questions

Should I buy or sell Masimo stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MASI shares.
View MASI analyst ratings
or view top-rated stocks.

What is Masimo's stock price forecast for 2022?

6 Wall Street analysts have issued 12-month price targets for Masimo's shares. Their MASI share price forecasts range from $135.00 to $295.00. On average, they anticipate the company's share price to reach $183.80 in the next twelve months. This suggests a possible upside of 19.1% from the stock's current price.
View analysts price targets for MASI
or view top-rated stocks among Wall Street analysts.

How have MASI shares performed in 2022?

Masimo's stock was trading at $292.78 at the beginning of 2022. Since then, MASI stock has decreased by 47.3% and is now trading at $154.37.
View the best growth stocks for 2022 here
.

When is Masimo's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 25th 2022.
View our MASI earnings forecast
.

How were Masimo's earnings last quarter?

Masimo Co. (NASDAQ:MASI) posted its quarterly earnings results on Tuesday, August, 9th. The medical equipment provider reported $1.35 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.16. The medical equipment provider earned $565.30 million during the quarter, compared to analyst estimates of $540.56 million. Masimo had a trailing twelve-month return on equity of 17.39% and a net margin of 12.68%. The company's quarterly revenue was up 87.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.94 EPS.

What guidance has Masimo issued on next quarter's earnings?

Masimo updated its FY22 earnings guidance on Tuesday, August, 9th. The company provided earnings per share guidance of $4.34-$4.57 for the period, compared to the consensus EPS estimate of $4.52. The company issued revenue guidance of $1.985-$2.045 billion, compared to the consensus revenue estimate of $2.04 billion.

What is Joe E. Kiani's approval rating as Masimo's CEO?

136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Masimo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO).

What is Masimo's stock symbol?

Masimo trades on the NASDAQ under the ticker symbol "MASI."

Who are Masimo's major shareholders?

Masimo's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (3.79%), Liontrust Investment Partners LLP (2.16%), Martin Currie Ltd. (1.07%), Assenagon Asset Management S.A. (0.99%), Northern Trust Corp (0.91%) and Deutsche Bank AG (0.88%). Insiders that own company stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Sanford Fitch, Steven Barker, Tao Levy, Thomas Samuel Mcclenahan and Yongsam Lee.
View institutional ownership trends
.

How do I buy shares of Masimo?

Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Masimo's stock price today?

One share of MASI stock can currently be purchased for approximately $154.37.

How much money does Masimo make?

Masimo (NASDAQ:MASI) has a market capitalization of $8.11 billion and generates $1.24 billion in revenue each year. The medical equipment provider earns $229.65 million in net income (profit) each year or $3.32 on an earnings per share basis.

How many employees does Masimo have?

The company employs 6,200 workers across the globe.

When was Masimo founded?

Masimo was founded in 1989.

How can I contact Masimo?

Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The official website for the company is www.masimo.com. The medical equipment provider can be reached via phone at (949) 297-7000, via email at ekammerman@masimo.com, or via fax at 949-297-7001.

This page (NASDAQ:MASI) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.